Carriage of mutations R462Q (rs 486907) and D541E (rs 627928) of the RNASEL gene and risk factors in patients with prostate cancer in Burkina Faso

Abstract

Background Prostate cancer (Pca) is a public health problem that affects men, usually of middle age or older. It is the second most common cancer diagnosed in men and the fifth leading cause of death. The RNASEL gene located in 1q25 and identified as a susceptibility gene to hereditary prostate cancer, has never been studied in relation to prostate cancer in Burkina Faso. The aim of this study was to analyze the carriage of RNASEL R462Q and D541E mutations and risks factors in patients with prostate cancer in the Burkina Faso. Methods This case–control study included of 38 histologically diagnosed prostate cancer cases and 53 controls (cases without prostate abnormalities). Real-time PCR genotyping of R462Q and D541E variants using the TaqMan® allelic discrimination technique was used. Correlations between different genotypes and combined genotypes were investigated. Results The R462Q variant was present in 5.3% of cases and 7.5% of controls. The D541E variant was present in 50.0% of cases and 35% of controls. There is no association between R462Q variants (OR = 0.60; 95%IC, 0.10–3.51; p = 0.686) and D541E variants (OR = 2.46; 95%IC, 0.78–7.80; p = 0.121) and genotypes combined with prostate cancer. However, there is a statistically significant difference in the distribution of cases according to the PSA rate at diagnosis (p ˂ 0.001). For the Gleason score distribution, only 13.2% of cases have a Gleason score greater than 7. There is a statistically significant difference in the Gleason score distribution of cases (p ˂ 0.001). Conclusions These variants, considered in isolation or in combination, are not associated with the risk of prostate cancer.

Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso

“…These results could be attributed to late diagnosis and the low rate of prostate cancer screening programs in Burkina Faso, highlighting the high PSA levels at diagnosis obtained in our study (mean 642.12 ± 1153.42 ng/ml). These levels are almost similar to those obtained (mean PSA of 537 ng/ml et 627.85 ng/ml) in a previous study in Burkina Faso [ 29 , 30 ]. Regarding the Gleason score, 73.65% of the patients had a Gleason score of 7 or higher.…”

“…Many studies have reported that black men are diagnosed with prostate cancer at a younger age [ 27 , 28 ]. We obtained a mean age of patients at diagnosis of 67.46 ± 8.03 years with an age range of 51 to 81 years, similar to the age range found in Burkina Faso in 2022 and Cameroon (67.8 ± 7.44 years) in 2019 [ 25 , 29 ]. These results could be attributed to late diagnosis and the low rate of prostate cancer screening programs in Burkina Faso, highlighting the high PSA levels at diagnosis obtained in our study (mean 642.12 ± 1153.42 ng/ml).…”